Boehringer Ingelheim and its subsidiary Boehringer Ingelheim Vetmedica Inc. reported Oct. 26 that it will acquire a “significant portion” of the Fort Dodge Animal Health business from Pfizer Animal Health. Terms of the deal were not disclosed.
Pfizer Inc., parent company of Pfizer Animal Health, recently acquired Wyeth and its subsidiary Fort Dodge Animal Health. Pfizer and Wyeth began joint operations on Oct. 16.
The Boehringer Ingelheim-Pfizer deal includes products in the United States, Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa. Products being acquired in Europe are still subject to approval by European anti-trust authorities.
As part of the deal, Boehringer Ingelheim will acquire the Duramune line of vaccines for dogs, the Fel-O-Vax line of vaccines for cats and the Rabvac line of rabies vaccines manufactured and sold in the United States, Canada and Australia. The company will also acquire a portfolio of pet and equine pharmaceutical products currently sold in the United States.
In addition, the company will acquire cattle vaccines in the United States and Canada, including the Triangle, Pyramid and Presponse vaccine lines. Pharmaceutical products being acquired include Cydectin (moxidectin) for cattle and sheep as well as Polyflex (ampicillin sodium). The dairy portfolio includes the brands Today and Tomorrow.
Several Canadian swine vaccines are also included in the acquisition as are some cattle vaccines sold in Europe and South Africa.
Boehringer Ingelheim is headquartered in Ingelheim, Germany, and Boehringer Ingelheim Vetmedica Inc. is based in St. Joseph, Mo. Pfizer is in New York.